Please login to the form below

Not currently logged in
Email:
Password:

inflammatory conditions

This page shows the latest inflammatory conditions news and features for those working in and with pharma, biotech and healthcare.

Sanofi and Ablynx sign €2.4bn nanobody deal

Sanofi and Ablynx sign €2.4bn nanobody deal

Sanofi and Ablynx sign 2.4bn nanobody deal. The duo will develop immune-mediated inflammatory disease candidates. ... Through external partnerships like these, combined with our internal R&D expertise, we aim to transform the treatment landscape for

Latest news

  • FDA verdict on Amgen's Humira biosimilar due in September FDA verdict on Amgen's Humira biosimilar due in September

    FDA verdict on Amgen's Humira biosimilar due in September. Begins review the version of AbbVie's big-selling anti-inflammatory drug. ... The US FDA has started its review of Amgen's biosimilar version of big-selling anti-inflammatory drug Humira, with an

  • Roche drops superbug partnership with Polyphor Roche drops superbug partnership with Polyphor

    Anti-Inflammatory deal. After jettisoning the Polyphor project, Roche added another research deal in the form of a licensing agreement for a novel, oral small molecule inhibitor of Vascular Adhesion Protein ... patients with various inflammatory

  • Novartis' Cosentyx cleared for wider use in Europe Novartis' Cosentyx cleared for wider use in Europe

    Cosentyx "has the potential to become a new standard of care for these common but under-treated inflammatory conditions," he added.

  • Lilly’s baricitinib beats Humira in trial for RA Lilly’s baricitinib beats Humira in trial for RA

    Baricitinib is a once-daily, oral, selective JAK1 and JAK2 inhibitor. JAK-dependant cytokines have been implicated in the pathogenesis of a number of inflammatory and autoimmune diseases, suggesting that they ... may be useful for the treatment of a

  • Pfizer eyes sepsis therapy via a stake in AM-Pharma Pfizer eyes sepsis therapy via a stake in AM-Pharma

    ATP release drives inflammation and tissue damage but reCAP can convert it to adenosine, which is thought to have anti-inflammatory and tissue protective effects. ... In addition to sepsis, reCAP could also have potential in other inflammatory conditions,

More from news
Approximately 1 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    49. Mesoblast / Celgene. Minority investment and option to license. stem-cell product candidates for conditions including inflammatory bowel disease and certain oncological indications.

  • Pharma deals in April 2015 Pharma deals in April 2015

    Celgene, will gain six months right of first refusal on Mesoblast's stem-cell product candidates for conditions including inflammatory bowel disease and certain oncological indications, for global rights (excluding Japan),

  • Deal Watch table for April 2014 Deal Watch table for April 2014

    7, 100. Questcor/ Mallinckrodt. Acquisition. Acthar Gel (repository corticotropin) for “ difficult-to-treat” autoimmune/ inflammatory conditions.

  • Pharma deals during April 2014 Pharma deals during April 2014

    This gives Mallinckrodt, Acthar Gel (repository corticotropin), which is FDA approved for 19 “ difficult-to-treat” autoimmune and inflammatory associated conditions and currently primarily used to treat multiple sclerosis relapses, proteinuria

  • Biosimilars: friend or foe for healthcare systems? Biosimilars: friend or foe for healthcare systems?

    Here we consider how the European landscape for biosimilars is ripe for transformation as more mAbs or anti-TNFs (Tumour Necrosis Factors) for inflammatory conditions such as rheumatoid arthritis enter the

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics